Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 9/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27465015 | 0.95 | TSHR (0.60) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL28290465 | 0.89 | ALDH1A1 (0.58) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL31657765 | 0.88 | TSHR (0.70) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL1308818 | 0.88 | TSHR (0.70) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL21143371 | 0.87 | ALDH1A1 (0.71) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL1813573 | 0.87 | ALDH1A1 (0.71) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL684368 | 0.87 | ALDH1A1 (0.71) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL18668786 | 0.84 | TSHR (0.65) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL27701080 | 0.84 | TSHR (0.83) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL28904646 | 0.83 | TSHR (0.67) | TSHRMAPK1CYP3A4TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055173-A1 | RELEASE OF STATINS IN THE INTESTINE | DEXCEL PHARMA TECHNOLOGIES LTD. (IL) | 2010-03-04 | — | — | US | claimed |
| CN-109563176-A | Cellulose acetate phthalate ether | 陶氏环球技术有限责任公司 | 2019-04-02 | — | — | CN | disclosed |
| US-7615233-B2 | Particulate construct comprising polyhydroxyalkanoate and method for producing it | CANON KABUSHIKI KAISHA (JP) | 2009-11-10 | — | — | US | disclosed |
| EP-1275378-B1 | Particulate construct comprising polyhydroxyalkanoate and method for producing it | CANON KK (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20030194443-A1 | Particulate construct comprising polyhydroxyalkanoate and method for producing it | CANON KABUSHIKI KAISHA (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1275378-A2 | Particulate construct comprising polyhydroxyalkanoate and method for producing it | CANON KABUSHIKI KAISHA (JP) | 2003-01-15 | — | — | EP | disclosed |
| EP-0142561-B1 | LONG-ACTING NIFEDIPINE PREPARATION | KANEBO, LTD. (JP) | 1989-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194443-A1 | Particulate construct comprising polyhydroxyalkanoate and method for producing it | SQLE, FDFT1, CYP51A1 | TSHR 2273/4885MAPK1 4268/4885CYP3A4 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.